Page last updated: 2024-12-05

oxyphencyclimine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxyphencyclimine is an anticholinergic drug that acts as a muscarinic antagonist. It was first synthesized in the 1950s and was originally used to treat gastrointestinal disorders like irritable bowel syndrome and peptic ulcer disease. Its anticholinergic properties reduce smooth muscle spasms in the gastrointestinal tract, relieving symptoms. However, due to its potential side effects, such as dry mouth, blurred vision, and urinary retention, its use has declined in recent years. Research on oxyphencyclimine focuses on its potential as an antispasmodic agent for treating gastrointestinal disorders, exploring its mechanisms of action and potential for safer formulations. It is also being studied for its potential in managing other conditions, such as Parkinson's disease and urinary incontinence, but these applications are still in their early stages.'

oxyphencyclimine: minor descriptor (65-85); on-line & Index Medicus search PYRIMIDINES (65-85); RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4642
CHEMBL ID1495
CHEBI ID7868
SCHEMBL ID250184
MeSH IDM0262977

Synonyms (71)

Synonym
DIVK1C_000876
KBIO1_000876
(1-methyl-1,4,5,6-tetrahydropyrimidin-2-yl)methyl cyclohexyl(hydroxy)phenylacetate
SPECTRUM_001606
SPECTRUM5_001499
benzeneacetic acid, .alpha.-cyclohexyl-.alpha.-hydroxy-, (1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)methyl ester
IDI1_000876
BSPBIO_003391
C07851
oxyphencyclimine
125-53-1
DB00383
oxyphencyclimine [inn:ban]
oxifencicliminum [inn-spanish]
oxiphencycliminum
einecs 204-743-3
oxyphencycliminum [inn-latin]
1,4,5,6-tetrahydro-1-methyl-2-pyrimidinylmethyl alpha-cyclohexyl-alpha-phenylglycolat
1,4,5,6-tetrahydro-1-methyl-2-pyrimidinemethanol-alpha-phenylcyclohexaneglycolate
1-methyl-1,4,5,6-tetrahydro-2-pyrimidinylmethyl-alpha-cyclohexylmandelat
KBIO2_002086
KBIOSS_002086
KBIOGR_000927
KBIO3_002894
KBIO2_007222
KBIO2_004654
NINDS_000876
SPECTRUM4_000234
SPECTRUM3_001806
SPBIO_001600
SPECTRUM2_001600
chebi:7868 ,
CHEMBL1495
L000910
D08325
oxyphencyclimine (inn)
(1-methyl-5,6-dihydro-4h-pyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
NCGC00018210-02
oxyphencycliminum
4v44h1o8xi ,
unii-4v44h1o8xi
oxifencicliminum
caridan
antulcus
naridan
zamanil
(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)methyl .alpha.-phenylcyclohexaneglycolate
oxyphencyclimine [mi]
oxyphencyclimine [who-dd]
oxyphencyclimine [vandf]
oxyphencyclimine [inn]
gtpl7256
(1-methyl-1,4,5,6-tetrahydropyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
SCHEMBL250184
daricon (salt/mix)
DUDKAZCAISNGQN-UHFFFAOYSA-N
vio-thene (salt/mix)
daricol (salt/mix)
(1-methyl-1,4,5,6-tetrahydro-2-pyrimidinyl)methyl cyclohexyl(hydroxy)phenylacetate #
ulcociclinina (salt/mix)
setrol (salt/mix)
AB00053686_09
DTXSID4023410
SBI-0051866.P002
Q1227228
BRD-A58193911-003-12-0
EN300-18563495
CS-0013722
HY-B0954A
benzeneacetic acid, a-cyclohexyl-a-hydroxy-,(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)methyl ester
AKOS040744834
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (81.48)18.7374
1990's3 (11.11)18.2507
2000's1 (3.70)29.6817
2010's1 (3.70)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.51 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.70%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (96.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]